Retatrutide is an investigational compound that has not been approved for human consumption or therapeutic use by any regulatory authority
You would have to take two 1.0mg injections, which is not cost efficacious. In final draft guidance, published on 8 September 2023, the National Institute for Health and Care Excellence (NICE) recommended tirzepatide for the treatment of T2DM, reversing its initial decision against use of the drug in June 2023
The release of their 2023 results merely confirmed what analysts had been predicting: the soaring success of their semaglutide-based drugs
In contrast, Mod GRF 1-29 primarily focuses on enhancing growth hormone release without significantly affecting appetite or cortisol levels
2030 (USD BILLION) FIGURE 15 GLP-1 AGONISTS MARKET, BY END USER, 2025 VS
But theyre basically saying, Look, we believe that peptides will be saved. In fact, pharmacists have pushed back against a regulatory process they describe as murky and unfair